An Observational Study of Adjuvant (Post-surgery) Therapy With Nivolumab for Resected (Completely Removed) Melanoma in Australia
This study is designed to estimate the effectiveness of nivolumab when given to participants after removing their cancer with surgery, over a 5-year follow-up, in real-world conditions in Australia.
Melanoma
DRUG: nivolumab
Percentage of Participants with Relapse-Free Survival (RFS), The time between the date of randomisation and the date of first recurrence, new primary melanoma, or death due to any cause, whichever occurred first., Up to 5 years post treatment initiation with adjuvant nivolumab therapy
Percentage of Participants with Distant Metastasis-Free Survival (DMFS), Up to 5 years post treatment initiation with adjuvant nivolumab therapy|Overall Survival (OS), Up to 5 years post treatment initiation with adjuvant nivolumab therapy|Description of sociodemographic profile of participants, At treatment initiation with adjuvant nivolumab therapy|Description of clinical characteristics of participants, At treatment initiation with adjuvant nivolumab therapy|Prior medical history of participants, At treatment initiation with adjuvant nivolumab therapy|Description of nivolumab pattern of use, At treatment initiation with adjuvant nivolumab therapy|Health-related quality of life (HRQOL) of participants as assessed by European Quality of Life Five Dimensional Scale (EuroQOL-5D/EQ-5D), Up to 5 years post treatment initiation with adjuvant nivolumab therapy|HRQOL of participants as assessed by European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ C-30), Up to 5 years post treatment initiation with adjuvant nivolumab therapy|HRQOL of participants as assessed by Functional Assessment of Cancer Therapy-Melanoma (FACT-M) questionnaire, Up to 5 years post treatment initiation with adjuvant nivolumab therapy|Participants' socioeconomic status as assessed by their highest education level, At treatment initiation with adjuvant nivolumab therapy|Description of care received as assessed by Healthcare Resource Utlization, During, and up to 5 years post discontinuation of nivolumab use|Number of participants experiencing immune-related Adverse Events (AEs), Up to 5 years post treatment initiation with adjuvant nivolumab therapy|Number of participants experiencing non-immune-related AEs, Up to 5 years post treatment initiation with adjuvant nivolumab therapy
This study is designed to estimate the effectiveness of nivolumab when given to participants after removing their cancer with surgery, over a 5-year follow-up, in real-world conditions in Australia.